A Japanese firm has won EU novel foods approval for a blood clot-benefitting fermented soy bean extract for all groups except “pregnant and lactating women.”
The application from Osake-based Japan Bio Science Laboratory (JBSL) is approved in all 28 EU member states after being written into Official Journal of the European Union on 20 January . JBSL received a positive opinion from the European Food Safety Authority (EFSA) last year.
The approval is for “non-genetically modified soy beans (Glycine max (L.)) with a selected strain of Bacillus subtilis var. natto.”.
The approved extract contain natto which is a source of vitamin K2 but in this case isolates to nattokinase which has been linked to anti-blood clotting and other circulation and heart health benefits.
Some EU member states had expressed concern about the nutrient’s blood clotting effects, but EFSA concluded JBSL’s NSK-SD branded ingredient was safe under the conditions proposed.
These were specified as “food supplements in capsule, tablet or powder form intended for the adult population, excluding pregnant and lactating women with a maximum dose of 100 mg fermented soybean extract per day.”
Medical supervision was advised if consumed with medicines.
Natto is popular in Japan, the US and is approved for sue in the food supply in more than 10 countries.